Andrew Gillis-Smith, MD
Hematology & Oncology · Worcester, MANPI 1063859387
Payments from drug & device makers
Across 56 payments — averaging $5005.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$212K
- Genentech, Inc.$68K
- Merck$111
- Novartis$98
- Genentech USA, Inc.$91
- Adaptive Biotechnologies Corporation$64
- plus $90 from 2 others
Across 4 payments — averaging $332.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$1K
- AbbVie$96
What the payments were for
- Food & beverage$39687%
- Education$5813%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $211,771 |
| Genentech, Inc. | 8 | $68,085 |
| Merck | 2 | $111 |
| Novartis | 1 | $98 |
| Genentech USA, Inc. | 1 | $91 |
| Adaptive Biotechnologies Corporation | 1 | $64 |
| E.r. Squibb & Sons, L.L.C. | 2 | $47 |
| Foundation Medicine, Inc. | 1 | $43 |
How this compares
$280,309 in reported general payments places this provider in the 70th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 41 | $477,326 |
| Acyclovir | 30 | $754 |
| Sertraline Hcl | 16 | $182 |
| Prednisone | 19 | $20 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Worcester
- Austin KimWorcester$19.3M
- Kriti MittalWorcester$1.7M
- William WalshWorcester$1.6M
- Jan CernyWorcester$1.5M
- Viola ZhuWorcester$1.5M
- Matthew DavidsBoston$58.6M
- Nadine TungBoston$32.4M
- Jorge CastilloBoston$31.2M
- Daniel DeangeloBoston$28.5M
- Sara TolaneyBoston$20.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.